Evidence map›Paper›PMID 41803986›Full record

ArticleBreast cancer research : BCR2026

CD19

Qiyi Zhou, Zhimin Zhu, Yuxin Zhao, Di Jing, Liyuan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qiyi ZhouCenter of PRaG Therapy, Center for Cancer Diagnosis and Treatment, Laboratory of Cancer Radioimmunotherapy, the Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Zhimin ZhuHunan Provincial Maternal and Child Health Care Hospital, Changsha, 410008, China.
Yuxin ZhaoKey Laboratory of Animal Biological Products & Genetic Engineering, Ministry of Agriculture and Rural, Sinopharm Animal Health Corporation Ltd, Wuhan, 430023, China.
Di JingDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Liyuan ZhangCenter of PRaG Therapy, Center for Cancer Diagnosis and Treatment, Laboratory of Cancer Radioimmunotherapy, the Second Affiliated Hospital of Soochow University, Suzhou, 215004, China. zhangliyuan@suda.edu.cn.

Funding

Internal Collaboration Project of the State Key Laboratory of Radiation Medicine and Radiation Protection GZN1202302National Natural Science Foundation of China 82573449, 82171828Suzhou Multidisciplinary Clinical Research Project for Major Diseases DZXYJ202304Talent Project of The Second Affiliated Hospital of Soochow University XKTJ-RC20240
6 · The paper itself

Abstract

backgroundAmong breast cancer subtypes, triple-negative breast cancer (TNBC) stands out for its aggressiveness and high frequency of brain metastases. However, the mechanisms driving BrM remain poorly understood.

methodsWe performed integrated single-cell RNA sequencing (scRNA-seq) analysis of TNBC among 15 patients (8 with metastases, 7 without) and combined these data with transcriptomic profiles of BrM from public datasets. B cell heterogeneity was characterized, and the prognostic value of cycling B cells (CD19

resultsscRNA-seq revealed significant enrichment of cycling B cells in metastatic TNBC. High abundance of CD19

conclusionsCD19

Indexed as

Antigens, CD19B-LymphocytesBrain NeoplasmsCytokinesNicotinamide PhosphoribosyltransferaseTriple Negative Breast NeoplasmsAnimalsBiomarkers, TumorCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansPrognosisSignal TransductionAntigens, CD19Biomarkers, TumorCytokinesNicotinamide PhosphoribosyltransferaseB cellsBrain metastasesTriple-negative breast cancerTumor microenvironment

Identifiers

PMID41803986
PMCPMC13085594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.